{"type": "table", "content": {"table": [["Primary Objective:", "Primary Endpoints:"], ["To compare the pharmacokinetics of PF-05221304 (both total and unbound) following administration of a single oral dose in adult subjects with varying degrees of hepatic impairment relative to age- and body weight-matched subjects without hepatic impairment.", "PF-05221304 PK parameters derived from plasma: Cmax, AUCinf, fu Cmax,u, and AUCinf,u-"], ["Secondary Objectives:", "Secondary Endpoints:"], ["To compare additional pharmacokinetic parameters (both total and unbound) of PF-05221304 following administration of a single oral dose in adult subjects with varying degrees of hepatic impairment relative to age-and body weight-matched subjects without hepatic impairment.", "PF-05221304 PK parameters derived from plasma: Tmax, AUClast, AUClast,u, CL/F, CLu/F, Vz/F, Vz.u/F and t1/2, as data permit."], ["To evaluate the safety and tolerability of a single oral dose of PF-05221304 when administered to adult subjects with varying degrees of hepatic impairment relative to age- and body weight-matched subjects without hepatic impairment", "Assessment of treatment-emergent adverse events, clinical laboratory tests, vital signs, and 12-lead ECGs."]], "pages": [9], "columns_matched": ["primary objective:", "primary endpoints:"], "rows": 5, "columns": 2}, "other_tables": {"0": {"table": [["Primary Objective:", "Primary Endpoints:"], ["To compare the pharmacokinetics of PF-05221304 (both total and unbound) following administration of a single oral dose in adult subjects with varying degrees of hepatic impairment relative to age- and body weight-matched subjects without hepatic impairment.", "PF-05221304 PK parameters derived from plasma: Cmax, AUCinf, fu Cmax,u, and AUCinf,u-"], ["Secondary Objectives:", "Secondary Endpoints:"], ["To compare additional pharmacokinetic parameters (both total and unbound) of PF-05221304 following administration of a single oral dose in adult subjects with varying degrees of hepatic impairment relative to age-and body weight-matched subjects without hepatic impairment.", "PF-05221304 PK parameters derived from plasma: Tmax, AUClast, AUClast,u, CL/F, CLu/F, Vz/F, Vz.u/F and t1/2, as data permit."], ["To evaluate the safety and tolerability of a single oral dose of PF-05221304 when administered to adult subjects with varying degrees of hepatic impairment relative to age- and body weight-matched subjects without hepatic impairment", "Assessment of treatment-emergent adverse events, clinical laboratory tests, vital signs, and 12-lead ECGs."]], "pages": [9], "columns_matched": ["primary objective:", "primary endpoints:"], "rows": 5, "columns": 2}}}